These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27618361)

  • 1. Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.
    Cabanillas F; Rivera N; Pardo WI
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):550-557. PubMed ID: 27618361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
    Conlan MG; Bast M; Armitage JO; Weisenburger DD
    J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
    Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
    Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
    Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lymphoma-like course in aggressive adult multisystem Langerhans cell histiocytosis and the benefit of PET/CT imaging in evaluation of diffuse metabolic activity of lung parenchyma].
    Szturz P; Adam Z; Rehák Z; Koukalová R; Kodet R; Nebeský T; Neubauer J; Moulis M; Smardová L; Mayer J
    Vnitr Lek; 2010 Nov; 56(11):1177-93. PubMed ID: 21250497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
    Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
    J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients.
    Chen-Liang TH; Martin-Santos T; Jerez A; Senent L; Orero MT; Remigia MJ; Muiña B; Romera M; Fernandez-Muñoz H; Raya JM; Fernandez-Gonzalez M; Lancharro A; Villegas C; Carlos Herrera J; Frutos L; Luis Navarro J; Uña J; Igua C; Sanchez-Vaño R; Cozar Mdel P; Contreras J; Sanchez-Blanco JJ; Perez-Ceballos E; Ortuño FJ
    Am J Hematol; 2015 Aug; 90(8):686-90. PubMed ID: 25925613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
    Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
    Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.